Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743366 · ClinicalTrials.gov registry record · Phase 2
Effect of Quetiapine on Marijuana Withdrawal and Relapse
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00743366 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 20 participants.
The verdict
NCT00743366, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objective of this study is to investigate the interaction between marijuana and quetiapine, with the goal of using this information to improve marijuana treatment outcome.
Interventions
- DRUG Placebo oral capsule
- DRUG Quetiapine
- DRUG Marijuana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743366
The ClinicalTrials.gov registry entry for NCT00743366 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT00743366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743366 about?
NCT00743366 is a clinical study titled "Effect of Quetiapine on Marijuana Withdrawal and Relapse". The objective of this study is to investigate the interaction between marijuana and quetiapine, with the goal of using this information to improve marijuana treatment outcome.
What is the current status of trial NCT00743366?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00743366?
The interventions under investigation include: Placebo oral capsule (DRUG), Quetiapine (DRUG), Marijuana (DRUG).
Who is sponsoring clinical trial NCT00743366?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.